Liu Rui, Zheng Hong-Gang, Li Wei-Dong, Hua Bao-Jin, Yao Bo, Qi Xin, Pei Ying-Xia, Zhang Yun
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
Cancer Institute of Beijing Guang'an Chinese Medicine, Beijing 100050, China.
Zhongguo Zhong Yao Za Zhi. 2018 Oct;43(19):3913-3918. doi: 10.19540/j.cnki.cjcmm.20180806.001.
The aim of this paper was to observe the effect of Feiliuping Gao and its combination with different types of drugs intervention on the expression of PI3K/AKT/NF-κB in lung metastatic microenvironment, and to reveal the advantage of Chinese medicine intervention time on the key molecule in lung metastatic microenvironment. The mouse model of Lewis lung carcinoma was established, and lung tissues were collected at 14 days, 21 days and 28 days after the intervention of Feiliuping Gao, and the expressions of PI3K, AKT and NF-κB were detected by immunohistochemistry and Western blot. At 14 days, there was no significant difference in PI3K expression between each group and the control group. The expression of AKT protein was significantly inhibited in the celecoxib (CLB) group, the Feiliuping Gao (FLP) combination with cyclophosphamide (FLP+CTX) group, and the Feiliuping Gao combination with celecoxib (FLP+CLB) group (<0.05). The inhibition of AKT protein expression in FLP+CLB group was superior. The FLP+CLB group can inhibit the expression of NF-κB protein (<0.05). At 21 days, compared with the control group, the expression of PI3K was inhibited in FLP group and the FLP+CTX group (<0.05), while the expression of PI3K was best inhibited in the FLP+CLB group (<0.001). Only the FLP+CLB group could significantly inhibit the expression of AKT protein (<0.01). The FLP+CTX group had the best effect in inhibiting the expression of NF-κB protein (<0.001). At 28 days, compared with the control group, the expression of PI3K and AKT was inhibited in the FLP+CLB group (<0.001). Feiliuping ointment combination with celecoxib has an advantage in regulating the expression of PI3K/AKT/NF-κB molecules in lung metastatic microenvironment.
本文旨在观察肺瘤平膏及其联合不同类型药物干预对肺转移微环境中PI3K/AKT/NF-κB表达的影响，揭示中药干预时间对肺转移微环境中关键分子的优势。建立Lewis肺癌小鼠模型，在肺瘤平膏干预后14天、21天和28天采集肺组织，采用免疫组化和Western blot检测PI3K、AKT和NF-κB的表达。14天时，各实验组与对照组PI3K表达差异无统计学意义。塞来昔布（CLB）组、肺瘤平膏（FLP）联合环磷酰胺（FLP+CTX）组、肺瘤平膏联合塞来昔布（FLP+CLB）组AKT蛋白表达显著受抑制（<0.05），其中FLP+CLB组对AKT蛋白表达的抑制作用更优。FLP+CLB组可抑制NF-κB蛋白表达（<0.05）。21天时，与对照组比较，FLP组和FLP+CTX组PI3K表达受抑制（<0.05），FLP+CLB组对PI3K表达抑制最佳（<0.001）。仅FLP+CLB组能显著抑制AKT蛋白表达（<0.01）。FLP+CTX组对NF-κB蛋白表达抑制效果最佳（<0.001）。28天时，与对照组比较，FLP+CLB组PI3K和AKT表达受抑制（<0.001）。肺瘤平膏联合塞来昔布在调控肺转移微环境中PI3K/AKT/NF-κB分子表达方面具有优势。
